Introduction
UEV1, also known as
CROC1[
1] or
CIR1[
2], encodes a ubiquitin (Ub)-conjugating enzyme variant (Uev) [
3]. It was also identified as a mammalian homolog of yeast
MMS2[
4] and as a co-factor of Ubc13 [
5]. Indeed, a Uev (Uev1A or Mms2) is absolutely required for Ubc13-mediated Lys(K)63-linked polyubiquitin chain assembly [
5‐
9]. Despite their shared biochemical activity, Mms2 and Uev1A appear to function differently in mammalian cells: Ubc13-Mms2 is required for DNA-damage responses whereas Ubc13-Uev1A is involved in nuclear factor κB (NF-κB) activation [
10]. Previous studies implicate
UEV1 as a potential proto-oncogene.
UEV1 was initially identified as a transactivator of the
c-fos promoter [
1]. It is downregulated when HT29-M6 colon cancer cells undergo chemical-induced differentiation, and upregulated when Simian virus 40-transformed human embryonic kidney cells become immortal [
2]. Furthermore,
UEV1 is variably upregulated in all tumor cell lines examined [
4], and maps to chromosome 20q13.2 [
3], a region where DNA amplification is frequently reported in breast cancers [
11‐
14] and other tumors [
15], as well as in virus-transformed immortal cells [
16].
Ubc13-Uev1A is involved in NF-κB activation [
10,
17,
18] and inhibits stress-induced apoptosis in HepG2 cells [
19]. Very recently, it was reported that a small-molecule inhibitor of Ubc13-Uev1A interaction can inhibit proliferation and survival of diffuse large B-cell lymphoma cells [
20]. These observations collectively establish a close correlation between
UEV1 expression and tumorigenic potential; however, whether
UEV1 plays a role in promoting tumorigenesis or progression and how this is accomplished remains to be elucidated.
NF-кB is a sequence-specific transcription factor known to be involved in innate immunity, anti-apoptosis and inflammation [
21‐
23], and its uncontrolled activation is associated with several types of cancers including breast cancer [
24,
25]. It regulates a panel of genes that collectively play pro-survival and anti-apoptotic roles [
26,
27]. It also controls the expression of genes linked with invasion, angiogenesis, and metastasis of cancer, including the matrix metalloproteinase (
MMP) family [
28,
29] and chemokine (C-X-C motif) ligand (
CXCL) family genes [
30,
31]. Activation of NF-κB is a tightly regulated event. In normal cells, NF-κB becomes activated only after the appropriate stimulation, and then it upregulates the transcription of its target genes [
24]. NF-κB is activated by many divergent stimuli, including proinflammatory cytokines such as TNF-α, IL-1b, epidermal growth factor (EGF), T- and B-cell mitogens and bacterial lipopolysaccharides (LPS) [
32]. Previous studies reported that the Uev1A-Ubc13 heterodimer is involved in TNF receptor-associated factor 6 (TRAF6) [
17,
33] and TRAF2-mediated [
34] activation of NF-κB, in which Ubc13-Uev1A probably serves as a unique Ubc/E2 along with TRAF proteins to polyubiquitinate NF-κB essential modulator/inhibitor of κB proteinkinase (NEMO/IKKγ) [
18,
35] and/or Rieske iron-sulfur polypeptide 1(RIP1) [
36] to activate IκB kinase (IKK). Activated IKK leads to the phosphorylation and degradation of IκBα, resulting in the release of NF-κB RelA (p65) subunits to translocate into the nucleus [
37].
In this study we demonstrate that in MDA-MB-231 breast cancer cells, the UEV1A transcript level is moderately elevated compared to normal breast cells. Overexpression of UEV1A alone in MDA-MB-231 cells is sufficient to activate NF-кB, which in turn upregulates the MMP1 expression to enhance breast cancer cell metastasis. More importantly, experimental depletion of Uev1 in MDA-MB-231 cells reduces MMP1 expression and reduces their ability to grow tumors and metastasize in a xenograft mouse model. These observations provide the experimental and theoretical cornerstone for therapeutic targeting of Uev1A in the treatment of metastatic breast cancers.
Methods
Cell culture
Human breast cancer cell lines MDA-MB-231, MCF7, MDA-MB-468, MDA-MB-361, MDA-MB-453, MDA-MB-436 and SK-BRIII were obtained from the American Type Culture Collection (ATCC, Manassan, VA, USA). The cells were cultured in Dulbecco’s minimum essential medium (DMEM) (Invitrogen, Burlington, ON, Canada) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen) in a 5% CO2 atmosphere at 37°C. The MCF10A immortalized human mammary epithelial cells were obtained from ATCC and cultured in DMEM/F12 medium supplemented with 10% horse serum, 100 units/ml penicillin, 100 μg/ml streptomycin (Invitrogen), 10 μg/ml insulin (Sigma, St. Louis, MO, USA), 100 ng/ml choleratoxin (Sigma), 0.5 mg/ml hydrocortisone (Sigma), and 20 ng/ml EGF (Peprotech). MDA-MB-231-TR stable cell lines were created by transfecting MDA-MB-231 cell lines with pLenti6-TR-lentivirus (Invitrogen) and selecting with 10 μg/ml blasticidin (Invitrogen).
Plasmids and pLentivirus vector preparation
Human
MMS2,
UEV1A, and
UEV1C open reading frames (ORFs) were PCR-amplified as
KpnI-
XhoI fragments and cloned into the pcDNA4.0/TO/HA(+) plasmid vector. The 1.9-kb human
MMP1 promoter sequence [GenBank: AJ002550.1] was PCR-amplified as a
KpnI-
HindIII fragment and then cloned into the same sites of pGL4.2 (Invitrogen). The NF-кB target site was subsequently mutated by site-directed mutagenesis using a quick-exchange method (Stratagene, La Jolla, CA, USA). The sense primer for creating the NF-кB binding site mutation is 5′-AAAGG CAGAA GGGAA CCTCA
AGAGG TTTTG AAGAG CCACC GTAAA GTGAG-3′ (mutated sequence italicized). The mutated Ubc13-binding site (F38E) in Uev1A was designed based on a previous study with Mms2-F13E [
9]. The modified sequence for
UEV1 small hairpin RNA (shRNA) delivered by lentiviral particles was from Santa Cruz Biotechnology, Inc (Dallas, Texas, USA). The lentiviral particle infection of breast cancer cells was performed following instructions of the supplier. The
MMP1 and
MMP9 small interfering RNAs (siRNAs) were purchased from Genepharma Co Ltd (Shanghai, China). The sequence for
MMP1 siRNA is 5′- GCGUGUGACAGUAAGCUAATT-3′ and that for
MMP9 siRNA is 5′-CGCUCAUGUACCCUAUGUATT-3′.
RNA preparation and real-time RT-PCR (qRT-PCR)
Total RNA was prepared from cultured breast cancer cells by using TRIzol reagent (Invitrogen). First-strand cDNA was synthesized from total RNA with SuperScript (Invitrogen) according to manufacturer’s instructions. The human breast cancer cDNAs TissueScan™ cancer qPCR Arrays (#BCRT102) were purchased from Origene (Beijing, China). The clinical information is shown on the website [
38] and Additional file
1. qRT-PCR analysis was performed on the iQ5 cycler (Bio-Rad, Hercules, CA, USA). The specific primer sets were as follows:
GADPH, 5′- GAAGGTGAAGGTCGGAGTC-3′ and 5′- GAAGATGGTGATGGGATTTC-3′;
UEV1, 5′- TCTCCACAGCAATCCTATGAGGTTGA-3′ and 5′- CCAACAGTCGGAAATTGCGAGGG-3′;
UEV1A, 5′- GAGAGGTTCAAGCGTCTTACCTGAA-3′ and 5′-ACTGTGCCATCTCCTACTCCTTTCT -3′;
UEV1C, 5′-GCAGCCACCACGGGCTCG-3′ and 5′- CAATTATCATCCCTGTCCATCTTGT-3′;
MMS2, 5′- CGCTTGTTGGAAGAACTTGA-3′ and 5′- CGGAGGAGCTTCTGGGTAT-3′;
MMP1 5′- AAATGCAGGAATTCTTTGGG-3′ and 5′-ATGGTCCACATCTGCTCTTG-3′;
MMP9 5′-CATCGTCATCCAGTTTGGTG-3′ and 5′- TCGAAGATGAAGGGGAAGTG-3′. The relative expression levels were calculated using the comparative cycle threshold (CT) method (2
-ΔCT) on the Bio-Rad iQ5 (Bio-Rad).
Luciferase reporter assay
Cells were seeded in 24-well plates at a density of 1 × 105. After 24 hr, the cells were transfected using X-tremeGENE HP DNA Transfection Reagent (Roche, Indianapolis, IN, USA). Briefly, luciferase reporter gene constructs (400 ng), pcDNA-Uevs plasmids (400 ng) and the pRL-SV40 Renilla luciferase construct (5 ng) (for normalization) were co-transfected into the wells. Cell extracts were prepared 48 hr after transfection and the luciferase activity was measured using the Dual-Luciferase reporter assay system (Promega, Madison, WI, USA).
Western blot analysis
Cells were grown to log phase and lysed in Dulbecco’s PBS (150 mM NaCl, 10 mM Na
2HPO
4 and 10 mM NaH
2PO
4, pH 7.4) with 1% SDS and the protease inhibitor cocktail for mammalian cells (Sigma-Aldrich). Total protein concentration was determined by the Bradford method using a commercial reagent from Bio-Rad. Cell extracts or purified proteins were electrophoresed in 10% or 15% SDS-polyacrylamide gel electrophoresis (PAGE) gels, transferred to polyvinyl difluoride (PVDF) membrane, and incubated with specific primary antibodies. Monoclonal antibodies (mAbs) LN2B (anti-Uev1) and 4E11 (anti-Ubc13) were from the laboratory stock [
10,
39]. Primary antibodies against HA (sc-7392), MMP1 (sc-30069), NF-κB (sc-372), Lamin B (sc-166729), β-tublin (sc-6216), and secondary goat anti-mouse antibody IgG-horseradish peroxidase (HRP) (sc-2005) and goat anti-rabbit IgG-HRP (sc-2004) antibody were from Santa Cruz. The P-IκBα antibody (#2859S) was from Cell Signaling Technology (Whitby, ON, Canada), while an anti-MMP9 antibody (ab38898) was from Abcam (Toronto, ON, Canada) and β-actin antibody (BM0627) was from Boster (Wunah, China).
Immunoprecipitation
We immunoprecipitated 1 mg of protein samples in a total volume of 1 ml with 2 μg of antibody and 20 μl of Protein-A beads (for rabbit polyclonal antibodies) or Protein-G beads (for mouse monoclonal antibodies). The samples were rotated at 4°C overnight. The beads were washed 4 times with 1 ml of cold NP40 lysis buffer containing protease inhibitors. The beads were then boiled for 10 minutes in the presence of 25 μl 2 × sample buffer and the released proteins fractionated by SDS-PAGE in 12% or 15% gels. Proteins were detected by immunoblotting as described above.
Cell invasion and migration assays
In vitro invasion assays were conducted using Transwells (Costar, Cambridge, MA, USA) with 8-μm-pore-size polycarbonate membrane filters in 24-well culture plates. The upper surface of the filter was coated with Matrigel (Becton Dickinson, Bedford, MA, USA) in a volume of 12.5 μl per filter. The Matrigel was dried and reconstituted at 37°C into a solid gel on the filter surface. The lower surface of the filter was coated in fibronectin (20 μg/ml), vitronectin (10 μg/ml), collagen IV (50 μg/ml), or 10% (BSA)-DMEM as chemoattractants. After starving in BSA-free DMEM overnight, 2 × 104 cells were seeded in the upper chamber. The cells were allowed to invade for 48 hr. Cells that invaded the lower surface of the filter were counted in five random fields under a light-microscope at high magnification. Experiments were conducted at least in triplicate. The in vitro cell migration ability was detected by wound healing assay or transwell assay without Matrigel coating. The wound healing assay was performed by seeding 2 × 105 cells onto 96-well plates. Confluent monolayers were wounded using a pipette tip. After 48 hr the cell migration distance was measured under a light-microscope at high magnification in at least three random fields. The transwell assay without Matrigel was conducted using Transwells with 8-μm-pore-size polycarbonate membrane filters in 24-well culture plates. The lower surface of the filter was coated with 10% BSA-DMEM as chemoattractants. After starving in a BSA-free DMEM medium overnight, 5 × 104 cells were seeded in the upper chamber. Cells were allowed to invade for 6 to 36 hr and those migrated to the lower surface of the filter were counted in five random fields under a light-microscope at high magnification. Experiments were conducted at least in triplicate.
The experimental mouse work followed the animal care protocol CNUAREB-2012002 approved by the Capital Normal University Animal Research Ethics Board and was conducted at the Peking University Health Science Center, China. For the tumorigenesis assays, 5 × 10
6 breast cancer cells were injected subcutaneously into the lateral flanks of 4- to 5-week-old BALB/c female nude mice. The palpable tumor diameters were measured once per week. Tumor length (L) and width (W) were measured with a caliper, and the volume (V) was calculated by the following equation:
The mice were sacrificed 6 weeks after cell injection. For experimental metastasis assays by intravenous (i.v.) injection, 2 × 105 breast cancer cells were injected into the tail veins of the 4- to 5-week-old female BALB/c nude mice. Endpoint assays were conducted 5 weeks after injection. Metastatic lung nodules 0.5 mm in diameter were counted. Analysis of variance (ANOVA) was used for statistical analyses. To ensure representative sampling of lung tumor nodules, four sections were made per lung at various depths along the coronal plane of the lung. The nodules per lung (four sections) were counted under a light-microscope.
Histopathology
Formalin-fixed lungs were paraffin-embedded, and tissue sections derived from tumor nodules or other tissues were stained with H&E to evaluate the morphology and invasiveness of breast cancer cells. Metastatic tumor nodules were counted throughout the entire lung section at all three depths under a light-microscope. Anti-Uev1A (LN1), anti-MMP1 (sc-30069) and NF-κB p65 (sc-372) primary antibodies from Santa Cruz were used for immunohistochemistry (IHC). TissueFocus™ breast cancer tissue microarrays (CT565863) for IHC were obtained from Origene (Beijing, China). Microscopic images were captured by a SPOT digital camera mounted in a light-microscope.
Preparation of nuclear fraction
HeLa cells were treated with 40 ng/ml TNF-α for 2 hr. Cells were washed, scraped with PBS, and centrifuged at 3,000 rpm at 4°C. The pellet was suspended in 10 mM Tris (pH 8.0) with 1.5 mM MgCl2, 1 mM dithiothreitol, and 0.1% NP-40, and incubated on ice for 15 minutes. Nuclei were separated from cytosol by centrifugation at 12,000 rpm at 4°C for 15 minutes. The cytosolic supernatants were removed and the precipitated pellets were suspended in 10 mM Tris (pH 8.0) containing 100 mM NaCl and stored on ice for 30 minutes. After agitation for 30 minutes at 4°C, the lysate was centrifuged at 12,000 rpm for 15 minutes at 4°C, and the supernatant was collected.
Electrophoretic mobility shift assay (EMSA)
The secquence of biotin-labelled sense NF-κB probe for EMSA is 5′-GAACCTCAGAGAACCCCGAAGAGCC-3′. The cold probe is the same NF-κB sequence without biotin label. The sequence of biotin-labelled mutated sense NF-κB probe is 5′-GAA CCTCA AGAGGTTTTG AAGAGCC-3′ (mutated sequence underlined): 1 ng of the probe was incubated together with 10 to 20 μg of cell extracts or 5 to 10 μg of nuclear extracts for 30 minutes at 25°C in a final volume of 20 μl. The binding reaction was subsequently separated on a 5.5-7% poly-acrylamide gel in 1x Tris-Borate-EDTA (TBE) buffer (90 mM Tris, 90 mM boric acid).
Statistical analysis
The statistical significance of differential findings between the experimental and control groups was determined by Student’s t-test as implemented by Microsoft Excel 2010 (*P <0.05, **P <0.01 and ***P <0.001).
Discussion
It has been reported previously that human cells contain two
UEV genes,
UEV1 and
MMS2, which share >90% amino acid sequence-identity in their core domains [
4]. Although both Uev1A and Mms2 proteins serve as cofactors for Ubc13-mediated K63-linked polyubiquitination, their biological functions are apparently distinct and only the Uev1A-Ubc13 complex is involved in NF-κB signaling [
10]. It has been puzzling us that Uev1A and Mms2 have different molecular weights and migrate differently; however, a monoclonal antibody capable of recognizing both purified Uev1A and Mms2 only detects a single band in western blot analysis, and siRNA depletion of either Mms2 or Uev1 only partially reduced the intensity of this band. A careful examination in this study reveals that in addition to the previously reported two
UEV1 splicing variants
UEV1A and
UEV1B[
1], cultured human cells contain a novel
UEV1 splicing variant,
UEV1C, lacking the N-terminal 30 amino acid unique region of Uev1A. The resulting 147-residue protein would co-migrate with Mms2 during electrophoresis. It turns out that the
UEV1C transcript is much more abundant than
UEV1A, and a Uev1-specific monoclonal antibody can detect cellular Uev1C but not Uev1A, unless the latter is experimentally overexpressed.
The current study investigates roles of UEV1A, UEV1C and MMS2 in tumorigenesis using a breast cancer model. With comparable levels of ectopic expression, it was found that only UEV1A, but not UEV1C or MMS2, is able to promote cell migration and invasion. Similarly, overexpression of UEV1A, but not UEV1C promotes tumor growth and metastasis in a xenograft mouse model. The above results are highly reliable, as the target gene expression is under tight regulation of a Tet-on promoter, and the phenotypes were only observed under Dox-induced conditions. In a reverse experiment, depletion of Uev1 in cultured breast cancer cells significantly reduces cell migration and invasion, as well as tumor growth and metastasis in a dose-dependent manner, indicating that the cellular Uev1 (presumbly Uev1A) level plays a critical role in breast tumorigenesis and metastasis.
To understand the molecular mechanism by which Uev1A promotes tumorigenesis, we demonstrated that overexpression of
UEV1A, but not
UEV1C or
MMS2, is able to promote IκBα phorsphorylation and NF-κB translocation into the nucleus, and that this effect absolutely relies on its physical interaction with Ubc13. It is conceivable that as previously reported, the Ubc13-Uev1A heteromider serves as an E2 to assemble K63-linked poly-Ub chains along with cognate really interesting new gene (RING)-finger E3s like TRAF2 and/or TRAF6 [
17,
34], which recruit K63 polyUb-binding proteins like NEMO [
18] and TAB2/3 [
47,
48] to phorsphorylate and subsequently degrade IκBα, leading to NF-κB activation.
NF-κB activation promotes the transcription of many downstream genes in the signaling cascade [
41]. However, the moderate level of NF-κB activation by
UEV1A overexpression does not appear to induce all NF-κB targeting genes. To understand how overexpression of
UEV1A leads to tumorigenesis and particularly metastasis in breast cancer cells, we surveyed NF-κB and metastasis-related genes and focused on two candidate genes,
MMP1 and
MMP9, both of which are highly induced upon
UEV1A overexpression. Experimental results as presented in this report indicate that both genes are tightly regulatd by cellular Uev1 levels; however, depletion of MMP9 was not as effective as that of MMP1 on cell migration and invasion. As ecotopic expression of
MMP1 to restore the wild-type level in Uev1-depleted cells also restored wild-type level of invasiveness, it is plausible to conclude that
MMP1 is the critical downstream effector of
UEV1A-induced breast cancer metastasis, although this study does not rule out the contributions of
MMP9 and possibly other genes. The signal transduction cascade of Uev1A → NF-κB → MMP1 → metastasis is further confirmed by showing that Uev1A-induced
MMP1 expression is dependent on both Ubc13 and the predicted NF-κB binding site located in the
MMP1 promoter. Although this report only presents data from one human breast cancer line, we have obtained comparable results with a different breast cancer cell line MCF7 (data not shown), indicating that the tumorigenic and metastatic effects of Uev1A is a general phenomenon in breast cancers.
While the experimental evidence as shown in this report clearly indicates that
UEV1A can function as a proto-oncogene, the clinical relevance of this finding awaits future investigation. Nevertheless, our limited TissueScan microarray data indicate a low (less than 2-fold) variation in
UEV1A transcript levels among five normal human breast samples, compared with an increase of up to 20-fold in some breast cancer samples. As NF-κB activation is commonly observed in breast cancers [
24,
25,
49] and
UEV1 upregulation is also frequently observed in breast cancer samples [
12‐
14] and in cultured tumor cell lines [
4], and is found to be correlated to tumorigenic indicators [
2,
3], it is conceivable that a certain percentage of breast cancer samples with NF-κB activation is due to elevated
UEV1A expression.
This study demonstrated that the N-terminal region of Uev1A is the molecular determinant of its cellular function(s) in the NF-κB signaling pathway. Although the exact cellular function of Uev1C remains a mystery, our previous studies [
10] have shown that truncated Uev1A missing the N-terminal 30 amino acids behaves like Mms2 in terms of subcellular localization and promotion of K63-linked di-Ub versus poly-Ub chains
in vitro, suggesting that Uev1C may play an Mms2-related role.
Given the importance of Uev1 in signaling and tumorigenesis, small-molecule inhibitors against Uev1 have been isolated [
20,
50] based on their interference with the Ubc13-Uev1A interaction, and one appears to be able to inhibit proliferation and survival of diffuse large B-cell lymphoma cells. It is unclear whether these inhibitors also interfere with the Ubc13-Mms2 interaction, as critical residues responaible for the heterdimer formation are conserved between Uev1 and Mms2 [
9]. Furthermore, this study provides evidence that a desired inhibitor should target the N-terminal region of Uev1A instead of the Ubc13-Uev1 interface. Hence, this report provides an experimental and theoretical cornerstone for future diagnosis and therapy by targeting Uev1A for the cure of breast cancer.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
ZW participated in the project design and carried out most experiments. SS carried out the MMP1 expression and restoration experiments in MDA-MB-231 cells and cell mobility analysis in MCF7 cells. ZZ carried out MMP1 and MMP9 depletion by siRNA and analysis in MDA-MB-231 cells, HeLa cell nuclear protein extraction, and participated in the animal studies. WZ was involved in project design and technical advice. WX conceived the study, participated in the project design, manuscript preparation and submission. All authors read and approved the final manuscript.